论文部分内容阅读
目的:探讨血浆纤溶醇原激活物抑制因子-1(PAI-1)、尿激酶纤溶酶原激活物(u-PA)、血管内皮生长因子(VEGF)在非霍奇淋巴瘤(NHL)中的表达及意义。方法:采用SABC免疫组化法检测上述指标在69例NHL中的表达。结果:PAI-1、u-PA、VEGF在非霍奇金淋巴瘤中表达率分别为62.31%,44.93%,34.78%,均显著高于正常淋巴结组织中的表达(P<0.05);VEGF在晚期非霍奇金淋巴瘤中表达率较早期组高;u-PA在伴有全身症状组中表达较高,u-PA(+)组治疗缓解率较u-PA(-)组低;PAI-1(+)组3年生存率明显低于PAI-1(-)组;PAI-1、u-PA、VEGF之间无协同表达。结论:PAI-1、u-PA、VEGF在NHL中的高表达,与NHL的生物学行为密切相关,应联合检测对NHL进行综合评价。
Objective: To investigate the effects of plasma PAI-1, uPA and VEGF on non-Hodgkin’s lymphoma (NHL) In the expression and significance. Methods: SABC immunohistochemical method was used to detect the above indexes in 69 cases of NHL. Results: The expression rates of PAI-1, u-PA and VEGF in non-Hodgkin’s lymphoma were 62.31%, 44.93% and 34.78%, respectively, which were significantly higher than those in normal lymph nodes (P <0.05) The expression rate of u-PA in patients with advanced non-Hodgkin’s lymphoma was higher than that in the early stage. The expression of u-PA was higher in patients with systemic symptoms than in u-PA (- The 3-year survival rate of -1 (+) group was significantly lower than that of PAI-1 (-) group. There was no synergistic expression between PAI-1, u-PA and VEGF. Conclusion: The high expression of PAI-1, u-PA and VEGF in NHL is closely related to the biological behavior of NHL. The combined detection of NHL and PAI-1 should be evaluated comprehensively.